Holen Sie sich die Stockscreener-App
21.91
11.44%
2.25
Handel nachbörslich:
22.20
0.29
+1.32%
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Enliven (ELVN) Initiates $200M Public Stock Offering | ELVN Stoc - GuruFocus
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The Malaysian Reserve
Enliven Therapeutics Inc (ELVN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Enliven to sell $200M in stock after positive drug trial - BizWest
Enliven Therapeutics prices $200 million public offering By Investing.com - Investing.com India
Enliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded Warrants - Nasdaq
Enliven Therapeutics prices $200 million public offering - Investing.com
Biotech Breakthrough: Enliven Therapeutics Secures Massive $200M Funding Backed by Goldman Sachs - Stock Titan
Enliven Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com
Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares - Nasdaq
Enliven Therapeutics Launches $200 Million Securities Offering - marketscreener.com
Enliven Therapeutics Announces Positive Phase 1 Trial Results - TipRanks
Enliven Therapeutics announces $200 million public offering - Investing.com
Form 424B5 Enliven Therapeutics, - StreetInsider
SEC Form 424B5 filed by Enliven Therapeutics Inc. - Quantisnow
Biotech Enliven Therapeutics Unveils Massive $200M Stock Offering with Pre-Funded Warrants Option - Stock Titan
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PR Newswire
California State Teachers Retirement System Buys 1,940 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Two Sigma Investments LP Has $329,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Bank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4% After Insider Selling - Defense World
Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
ELVN Stock Price and Chart — NASDAQ:ELVN - TradingView
Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings? - Defense World
(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
BNP Paribas Financial Markets Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN Q2 Earnings? - Defense World
Enliven Therapeutics (ELVN) Gets a Buy from Mizuho Securities - The Globe and Mail
Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating - marketscreener.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Increased by Deutsche Bank AG - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.25 Consensus PT from Analysts - Defense World
Enliven Therapeutics to Present at Upcoming Investor Conferences - Nasdaq
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics chief scientific officer sells $81,533 in stock - Investing.com Australia
Enliven Therapeutics chief scientific officer sells $81,533 in stock By Investing.com - Investing.com India
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Northern Trust Corp - Defense World
HC Wainwright Issues Pessimistic Outlook for ELVN Earnings - Defense World
Jones Trading Has Lowered Expectations for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Q1 Earnings Forecast for ELVN Issued By HC Wainwright - Defense World
HC Wainwright Raises Enliven Therapeutics (NASDAQ:ELVN) Price Target to $40.00 - Defense World
Jones Trading Lowers Price Target for Enliven Therapeutics (ELVN) | ELVN Stock News - GuruFocus
Enliven (ELVN) Stock Target Cut Amid Mixed Market Reaction | ELVN Stock News - GuruFocus
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Holdings Lifted by Price T Rowe Associates Inc. MD - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 7.6% Following Weak Earnings - Defense World
Enliven Therapeutics Reports Q1 Results and Pipeline Progress - TipRanks
Enliven Therapeutics stock target raised to $40 at H.C. Wainwright By Investing.com - Investing.com South Africa
Enliven Therapeutics: Cash runway can fund ops through late 2027 - BizWest
Enliven Therapeutics (ELVN) Target Price Raised by HC Wainwright & Co. | ELVN Stock News - GuruFocus
Enliven Therapeutics stock target raised to $40 at H.C. Wainwright - Investing.com Australia
H.C. Wainwright Increases Price Target for Enliven (ELVN) Post Q - GuruFocus
H.C. Wainwright Increases Price Target for Enliven (ELVN) Post Q1 Report | ELVN Stock News - GuruFocus
Enliven reports positive Phase 1 trial data for ELVN-001 in CML - Investing.com Nigeria
Tower Research Capital LLC TRC Boosts Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - PR Newswire
Enliven reports positive Phase 1 trial data for ELVN-001 in CML By Investing.com - Investing.com South Africa
Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile - marketscreener.com
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress - The Malaysian Reserve
Enliven (ELVN) Reports Positive Results from ENABLE Trial for Chronic Myeloid Leukemia | ELVN Stock News - GuruFocus
Breakthrough CML Drug ELVN-001 Achieves 44% Response Rate in Heavily Pretreated PatientsKey Data Revealed - Stock Titan
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):